Top News
Active Surveillance Deemed “Justifiable” Option for Metastatic Renal Cell Carcinoma
Ureteroscopic Biopsy in UTUC May Increase Risk of Intravesical Recurrence
Pandemic Caused Cancer Screening Deficits in 2020
Anti-PD-1 Therapy Is Associated With Chronic Immune-Related Adverse Events in Patients With Melanoma
Cancer Diagnoses Increase at Age 65, Decrease Immediately Afterward
Serious Long-Term Adverse Events Decreased in Pediatric Hodgkin Lymphoma
Salvage Cryotherapy for Recurrent PCa May Provide Long-Term Oncologic Control
Outcomes Remain Poor for Colorectal Cancer Patients with Brain Metastases
Extended Regimen With Carfilzomib, Lenalidomide, and Dexamethasone Is Effective in Newly Diagnosed Multiple Myeloma
Complete TURBT Before Neoadjuvant Chemotherapy Improves MIBC Outcomes
Current State of Treatments for Cancer-Associated Venous Thromboembolism
EDITORIAL ADVISORY BOARD
E. David Crawford, MD
Jeffrey M. Farma, MD
Featured
-
Exploring the Bone Marrow Microenvironment of Myeloma Cells
The immune cells in the microenvironment can reign in myeloma cells but become suppressed and dysregulated during disease progression. -
Digital Mammography, Detection Rates of DCIS
The higher contrast of this tool is better than film-screen mammography at detecting calcifications that are key to diagnosing DCIS. -
RB-RECIST Criteria May Improve Retinoblastoma Management
In an international, multicenter collaboration, experts modified the RECIST criteria for use as objective endpoints in clinical trials of retinoblastoma therapies. -
Disruptions to Lung Cancer Treatment During the COVID-19 Pandemic
Throughout the COVID-19 pandemic, clinicians who care for patients with lung cancer have made multiple treatment approach changes for this vulnerable population. -
Recommendations From FDA-AACR Workshop to Increase African American Representation in Multiple Myeloma Clinical Trials
A workshop was convened by the US Food and Drug Administration and the American Association for Cancer Research to create recommendations for trial design and later stages of drug development in multiple myeloma. -
Socioeconomics and Cognitive Function After Childhood Brain Tumors
Researchers hope their findings could lead to targeted interventions to improve cognitive outcomes in pediatric brain tumor survivors from families with low socioeconomic status. -
COVID-19 Vaccination and Imaging Misinterpretation
Oncologists and patients should be aware of the potential manifestations of the COVID-19 vaccination on imaging and the consequences this might have on disease assessment, treatment monitoring, and decision-making.
More Features
Review of Barriers to Colorectal Cancer Screening in Hard-to-Reach Populations
The COVID-19 pandemic sheds new light on existing access challenges in preventive health care.
Therapeutic Approaches to Multiple Myeloma: An Interview With Ajai Chari, MD
Ajai Chari, MD, of Mount Sinai Hospital in New York City, provides his perspective on the current state of care in multiple myeloma.
NCCN Releases First Practice Guidelines for Wilms Tumor
New NCCN guidelines for Wilms tumor contain up-to-date information on screening, diagnosis, risk stratification, and treatment for this rare childhood renal cancer.
Pediatric Cancer Survivors and Diabetes: What Are the Risks?
Diabetes and metabolic syndrome represent two of the most common long-term complications in survivors of childhood cancer.
Tepotinib Now Approved to Treat NSCLC With MET Exon 14 Skipping Alterations
Xiuning Le, MD, PhD, discusses the future of tepotinib in the treatment of NSCLC. Dr Le is an author of a phase 2 study on tepotinib, a highly selective MET inhibitor.
-
Loading...
-
Loading...
